Access Becomes the Next Challenge as Gene Therapies Move Deeper Into Cancer Care
For many cancer specialists, the conversation around gene therapy is shifting from scientific feasibility to patient access. More therapies are moving through development and gaining regulatory support, yet receiving treatment still depends on factors that extend well beyond clinical eligibility. Manufacturing timelines, referral pathways and reimbursement policies are becoming just as influential as the therapies themselves.
CAR-T cell therapy illustrates that shift. The treatment has changed outcomes for certain blood cancers by genetically modifying a patient's own immune cells to recognize and attack cancer. Even as the technology matures, delivering it to patients remains a complex process that involves specialized manufacturing, careful coordination between treatment centers and payer approval.
Many gene therapies are still available only through specialized treatment centers that have the experience and facilities needed to deliver them safely. While that has helped establish consistent standards of care, it also means many patients must travel long distances to receive treatment. Extra referrals, scheduling requirements and administrative approvals can slow the process at a time when treatment decisions often need to be made quickly.
Paying for these therapies remains another obstacle. A recent cross-sectional study of commercial CAR-T therapies across G20 countries found that fewer than half of approved indications were covered through public reimbursement. The gap reflects a broader challenge facing healthcare systems as they weigh the cost of complex, personalized therapies against growing demand for access.
Healthcare providers are also evaluating whether more treatment can be delivered outside large academic hospitals. Community oncology practices have shown growing interest in expanding access, but clinicians point to staffing requirements, emergency care coordination and financial sustainability as issues that must be addressed before wider adoption becomes practical. Even where outpatient treatment is possible, implementation often requires months of planning before the first patient can be treated.
Developers are responding by looking for ways to shorten production timelines and simplify delivery. Several companies are working on manufacturing approaches designed to reduce the time needed to prepare personalized cell therapies. Faster production could help patients begin treatment sooner while easing pressure on treatment centers that manage limited manufacturing capacity. Some recent announcements have also focused on reducing production costs, although those approaches will require broader validation as they move toward commercial use.
The discussion is gradually moving beyond whether gene therapies can treat cancer effectively. Equal attention is being given to how patients reach those therapies once they become available. Questions about referral networks, reimbursement and treatment capacity are increasingly shaping adoption decisions across healthcare systems. As more gene therapies enter clinical practice, expanding access may become one of the defining issues for the next stage of cancer care.
